Research programme: antibacterials - Nemesis Bioscience

Drug Profile

Research programme: antibacterials - Nemesis Bioscience

Alternative Names: Nemesis Symbiotics

Latest Information Update: 10 Mar 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Nemesis Bioscience
  • Class Antibacterials; Gene therapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Bacterial infections

Most Recent Events

  • 15 Feb 2017 Nemesis Biosciences files for patent protection for its technologis and therapeutic approaches (Nemesis Biosciences website, February 2017)
  • 11 Jul 2016 Preclinical trials in Bacterial infections in United Kingdom (Topical)
  • 11 Jul 2016 Preclinical trials in Bacterial infections in United Kingdom (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top